• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    K Health Expands Board and Executive Team Amid Continued Demand for Virtual Care

    5/19/21 9:00:00 AM ET
    $TEVA
    $SGFY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Retail: Computer Software & Peripheral Equipment
    Technology
    Get the next $TEVA alert in real time by email

    Healthcare Veteran and General Counsel Join Company to Support Growing Momentum

    K Health, the 24/7 primary care system, announced today the appointment of Vivian Riefberg to its board. Riefberg is a board member at Johns Hopkins Medicine, PBS, and Signify Health (NYSE:SGFY) and the former co-leader of the health services practice at McKinsey & Company. K Health also announced that Chen Yehudai, former Vice President and General Counsel at Teva Pharmaceuticals (NYSE:TEVA), has joined its executive team as the company's first General Counsel.

    With over 4 million users, K Health's base continues to grow, with demand increasing rapidly since the start of the pandemic. Riefberg and Yehudai will help scale and develop the product in anticipation of continued growth.

    Vivian Riefberg brings over 30 years of experience in the global healthcare industry to the K Health board of directors. As a Senior Partner and former board member at McKinsey & Company, she co-led the firm's health services practice, led the public sector practice, and spent more than three decades serving clients across the healthcare ecosystem. She is a Professor of Practice at the University of Virginia Darden School of Business and a Director Emeritus at McKinsey & Company.

    "K Health has the potential to reduce annual medical costs by billions of dollars through its approach to tackling the biggest healthcare issues," said Riefberg. "With partnerships involving the largest players in the industry, I am honored to join a company that is working towards providing affordable, convenient and quality care to millions of people, especially as we navigate through the COVID-19 pandemic and beyond."

    "We're thrilled for Vivian to bring a unique and fresh perspective to our board," said Allon Bloch, K Health's CEO and co-founder. "She's joining a passionate group of similar-minded people who, like everyone at K, are dedicated to changing how we all approach healthcare."

    Chen Yehudai joins K Health as its first General Counsel. In this role, Yehudai will lead K Health's legal and compliance functions. She previously spent more than 13 years at Teva Pharmaceuticals, where she was the Vice President and General Counsel of Global Antitrust and Global HR and Corporate Affairs. Prior to Teva she was an Associate at Skadden, Arps, Slate, Meaghar & Flom in New York City. She holds an LL.M. and a doctoral degree (JSD) from Columbia University School of Law.

    Last month, K Health announced the formation of Hydrogen Health, a joint venture with Anthem and Blackstone to advance high quality digital and affordable healthcare. In January 2021, K Health announced K Pediatrics, an offering with insights and care for children aged 3-17 that's free with a K Health membership. K Health has also partnered with Baltimore City Public Schools, Boost Mobile, and Louisiana State University in an effort to make 24/7 access to doctors a reality for everyone in the U.S.

    About K Health

    K Health, headquartered in New York, is the digital healthcare company on a mission to use the power of shared knowledge to get everyone access to better, affordable healthcare—whenever, wherever they need it. K Health is a free tool that uses AI to help people understand how doctors diagnose and treat those with similar symptoms and conditions (aka "People Like Me"). Its data-driven platform consolidates the knowledge of thousands of doctors and billions of clinical data insights to get people trusted information and treatment. K Health also offers the option to chat with a clinician without insurance for less than a copay. K Health treats almost all primary care conditions, as well as anxiety and depression, and offers customizable treatment plans and prescriptions.

    Frequently the #1 downloaded app in the App Store's medical category, K Health is available in all 50 states and has helped over 4 million people get access to higher quality and affordable care. For more information, please visit www.khealth.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20210519005263/en/

    Get the next $TEVA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TEVA
    $SGFY

    CompanyDatePrice TargetRatingAnalyst
    Teva Pharmaceutical Industries Limited
    $TEVA
    12/9/2025$35.00Overweight
    Barclays
    Teva Pharmaceutical Industries Limited
    $TEVA
    12/5/2025$35.00Sector Outperform
    Scotiabank
    Teva Pharmaceutical Industries Limited
    $TEVA
    6/6/2025$24.00Buy
    Goldman
    Teva Pharmaceutical Industries Limited
    $TEVA
    5/28/2025$25.00Buy
    Truist
    Teva Pharmaceutical Industries Limited
    $TEVA
    5/12/2025$23.00Neutral → Overweight
    Analyst
    Teva Pharmaceutical Industries Limited
    $TEVA
    7/10/2024$20.00Hold → Buy
    Argus
    Teva Pharmaceutical Industries Limited
    $TEVA
    3/8/2024$14.00Underweight → Neutral
    JP Morgan
    Teva Pharmaceutical Industries Limited
    $TEVA
    2/12/2024$12.00 → $19.00Neutral → Overweight
    Piper Sandler
    More analyst ratings

    $TEVA
    $SGFY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief Legal Officer Mcavoy David R. bought $20,988 worth of Ordinary Shares (1,113 units at $18.86), increasing direct ownership by 9% to 13,027 units (SEC Form 4)

    4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

    9/9/25 4:02:56 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TEVA
    $SGFY
    SEC Filings

    View All

    Teva Pharmaceutical Industries Limited filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)

    12/11/25 4:31:29 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Teva Pharmaceutical Industries Limited

    10-Q - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)

    11/5/25 4:07:23 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Teva Pharmaceutical Industries Limited

    SCHEDULE 13G/A - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)

    11/5/25 11:49:28 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TEVA
    $SGFY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Teva Releases Q4 2025 Aide Memoire

    TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q4 2025 Aide Memoire is available on the "Investors" page on its website. Q4 2025 Aide Memoire Teva has compiled this document with public information that was previously provided by Teva in order to assist investors ahead of fourth quarter 2025 results, which are expected to be released on Wednesday, January 28, 2026 at 7am ET, followed by a conference call at 8am ET. The document is based on Teva's prior results, management's previous commentary about Teva's business outlook and data from select independent sources. About Teva Teva Pharmaceutical Indu

    12/12/25 4:30:00 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026

    TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter 2025 financial results on Wednesday, January 28, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations. Following the conclusion of the call, a replay of the webcast will be available within 2

    12/12/25 4:30:00 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

    Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation, for a broad patient population1Olanzapine LAI is designed to help support real-world adherence and improved stability, with the goal of addressing a critical treatment gap for people living with schizophrenia1Teva is committed to advancing this innovative treatment option and further build on its differentiated LAI franchise PARSIPPANY, N.J. and TEL AVIV, Israel, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the submission of a New Drug Application

    12/9/25 8:00:00 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TEVA
    $SGFY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Teva Pharma with a new price target

    Barclays initiated coverage of Teva Pharma with a rating of Overweight and set a new price target of $35.00

    12/9/25 8:54:12 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scotiabank initiated coverage on Teva Pharma with a new price target

    Scotiabank initiated coverage of Teva Pharma with a rating of Sector Outperform and set a new price target of $35.00

    12/5/25 8:41:58 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Teva Pharma with a new price target

    Goldman initiated coverage of Teva Pharma with a rating of Buy and set a new price target of $24.00

    6/6/25 8:33:51 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TEVA
    $SGFY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Exec. VP, European Commercial Daniell Richard exercised 115,468 units of Ordinary Shares at a strike of $18.40 and sold $3,311,126 worth of Ordinary Shares (115,468 units at $28.68) (SEC Form 4)

    4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

    12/11/25 4:09:26 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    See "Remarks" Sabag Mark sold $6,230,754 worth of Ordinary Shares (216,892 units at $28.73) and exercised 118,724 units of Ordinary Shares at a strike of $18.61, decreasing direct ownership by 65% to 52,828 units (SEC Form 4)

    4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

    12/11/25 4:06:35 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lichtenstein Chen converted options into 4,804 units of Ordinary Shares (SEC Form 4)

    4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

    12/4/25 4:01:55 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TEVA
    $SGFY
    Financials

    Live finance-specific insights

    View All

    Teva Releases Q4 2025 Aide Memoire

    TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q4 2025 Aide Memoire is available on the "Investors" page on its website. Q4 2025 Aide Memoire Teva has compiled this document with public information that was previously provided by Teva in order to assist investors ahead of fourth quarter 2025 results, which are expected to be released on Wednesday, January 28, 2026 at 7am ET, followed by a conference call at 8am ET. The document is based on Teva's prior results, management's previous commentary about Teva's business outlook and data from select independent sources. About Teva Teva Pharmaceutical Indu

    12/12/25 4:30:00 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026

    TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter 2025 financial results on Wednesday, January 28, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations. Following the conclusion of the call, a replay of the webcast will be available within 2

    12/12/25 4:30:00 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS

    For an accessible version of this Press Release, please visit www.tevapharm.com Teva reports revenues of $4.5 billion in the third quarter of 2025, an increase of 3% year-over-year (YoY) in U.S. dollars or 1% in local currency (LC). Excluding Japan BV in Q3 2024, revenues increased 5% in U.S. dollars or 3% in LC. United States segment increased by 12%; Europe segment decreased by 10% in LC; and International Markets segment decreased by 10% in LC, or increased by 2% in LC excluding Japan BV in Q3 2024, all compared to the third quarter of 2024.GAAP operating income margin of 19.7% and non-GAAP operating income margin of 28.9% (+86 bps YoY), driven by our key innovative brands' growth. On tr

    11/5/25 7:00:00 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TEVA
    $SGFY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Teva Pharmaceutical Industries Limited

    SC 13G - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)

    11/12/24 10:34:14 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Teva Pharmaceutical Industries Limited (Amendment)

    SC 13G/A - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)

    4/9/24 10:26:26 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Teva Pharmaceutical Industries Limited

    SC 13G - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)

    2/1/24 8:03:56 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TEVA
    $SGFY
    Leadership Updates

    Live Leadership Updates

    View All

    Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma's Biggest Challenges

    First cohort features 7 real-world challenges across R&D, manufacturing and supply chain, commercial and medical affairs Teva's first-ever global innovation platform aims to accelerate patient impact and drive business transformation, as part of its Pivot to Growth StrategyRise will enable startups and tech players worldwide to validate their solutions in real-world settings, scaling impact across Teva's global ecosystem including in the U.S., Europe, Israel and beyond TEL AVIV, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today unveiled Teva Rise, a global open innovation platform designed to harness the power of a variety of disruptive tech

    11/19/25 8:00:00 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

    USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns 

    6/26/25 11:44:00 AM ET
    $ADCT
    $CTOR
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Matthew Shields as Executive Vice President of Teva Global Operations (TGO), the Company's manufacturing and supply division, effective June 3, 2024. Mr. Shields succeeds Eric Drapé, who is leaving after 11 years with the Company, including more than four years as Executive Vice President, Global Operations. Mr. Shields will be a member of Teva's Executive Leadership Team and report directly to President and CEO Richard Francis. He will be based in Teva's U.S. headquarters in Parsippany, NJ. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2

    5/15/24 8:15:00 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care